A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

NCT01672476 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 293

Last updated 2016-07-01

No results posted yet for this study

Summary

A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension

Conditions

Interventions

DRUG

Placebo

Placebo

DRUG

Valsartan

Valsartan 80mg

DRUG

Fimasartan

Fimasartan 30mg

Sponsors & Collaborators

  • Bucheon St. Mary's Hospital

    collaborator OTHER
  • Konyang University Hospital

    collaborator OTHER
  • Korea University Anam Hospital

    collaborator OTHER
  • National Health Insurance Service Ilsan Hospital

    collaborator OTHER
  • Daegu Fatima Hospital

    collaborator OTHER
  • Dong-A University

    collaborator OTHER
  • Soon Chun Hyang University

    collaborator OTHER
  • Asan Medical Center

    collaborator OTHER
  • Gangnam Severance Hospital

    collaborator OTHER
  • Severance Hospital

    collaborator OTHER
  • Ulsan University Hospital

    collaborator OTHER
  • Kangbuk Samsung Hospital

    collaborator OTHER
  • Sejong General Hospital

    collaborator OTHER
  • Ewha Womans University Mokdong Hospital

    collaborator OTHER
  • Jeju National University Hospital

    collaborator OTHER
  • Hallym University Medical Center

    collaborator OTHER
  • Hanyang University

    collaborator OTHER
  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Seok Min Kang, M.D., Ph.D. · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-03-31
Completion
2013-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01672476 on ClinicalTrials.gov